These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 2949097)

  • 21. [Relationship between uremia polyneuropathy, uremic glucose metabolism disorder and severity of uremic intoxication in dialysis patients].
    Goubeaud G; Kunze K; Hohmann KH; Schütterle G; Biro G
    Verh Dtsch Ges Inn Med; 1974; 80():728-31. PubMed ID: 4454650
    [No Abstract]   [Full Text] [Related]  

  • 22. Plasma 3-deoxyglucosone elevation in chronic renal failure is associated with increased aldose reductase in erythrocytes.
    Hasuike Y; Nakanishi T; Otaki Y; Nanami M; Tanimoto T; Taniguchi N; Takamitsu Y
    Am J Kidney Dis; 2002 Sep; 40(3):464-71. PubMed ID: 12200796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Muscle glucose content and hexokinase activity in patients with chronic uremia.
    Fiaschi E; Campanacci L; Guarnieri GF; Faccini L; Bellini G; Carretta R; D'Angelo A
    Kidney Int Suppl; 1975 Feb; (3):341-4. PubMed ID: 1057708
    [No Abstract]   [Full Text] [Related]  

  • 24. An update on uremic toxins.
    Ringoir S
    Kidney Int Suppl; 1997 Nov; 62():S2-4. PubMed ID: 9350668
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Myocardial metabolism in experimental uremia].
    Minkin RB; Orlov AV; Klemina IK; Loktionov AS
    Patol Fiziol Eksp Ter; 1985; (3):28-31. PubMed ID: 4034252
    [No Abstract]   [Full Text] [Related]  

  • 26. Reduced postheparin plasma diamine oxidase activity in patients with chronic renal failure.
    Stein J; Scheuermann EH; Yazdi R; Lembcke B; Caspary WF
    Z Gastroenterol; 1994 Apr; 32(4):236-9. PubMed ID: 8017098
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Zinc metabolism in uremia.
    Mahajan SK; Prasad AS; Rabbani P; Briggs WA; McDonald FD
    J Lab Clin Med; 1979 Nov; 94(5):693-8. PubMed ID: 501198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cholinesterase levels in uremic man and renal allografted man.
    Hesse VE; Mostert JW; Moore RH; Murphy GP
    J Surg Oncol; 1970; 2(1):69-75. PubMed ID: 4939049
    [No Abstract]   [Full Text] [Related]  

  • 29. [Monoamine oxidase activity in patients with chronic renal failure and in experimental uremia in rats].
    Ksiazek A
    Pol Arch Med Wewn; 1978 Aug; 60(2):147-51. PubMed ID: 714710
    [No Abstract]   [Full Text] [Related]  

  • 30. Neuraminidase-like activity in sera of uremic anemic patients.
    Levinsky H; Gafter U; Levi J; Allalouf D
    Nephron; 1984; 37(1):35-8. PubMed ID: 6717703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic acidosis and uremic toxicity: protein and amino acid metabolism.
    Price SR; Mitch WE
    Semin Nephrol; 1994 May; 14(3):232-7. PubMed ID: 8036357
    [No Abstract]   [Full Text] [Related]  

  • 32. [Treatment of uremic symptoms and its metabolic consequences].
    Forsström J
    Duodecim; 1979; 95(22):1526-32. PubMed ID: 527518
    [No Abstract]   [Full Text] [Related]  

  • 33. Glucose metabolism in non-diabetic and insulin-dependent diabetic subjects with end-stage renal failure.
    Schmitz O
    Dan Med Bull; 1991 Feb; 38(1):36-52. PubMed ID: 2026051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Erythrocyte enzymes in chronic kidney failure].
    Khlebarova M; Dishlianova B; Belovezhdov N; Robeva R; Savova R
    Vutr Boles; 1985; 24(1):120-7. PubMed ID: 4024601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Blood platelet enzymes in hyperazotemia].
    Nenci GG; Notaristefano A
    Haematologica; 1971; 56(9):333-42. PubMed ID: 4401870
    [No Abstract]   [Full Text] [Related]  

  • 36. Uremic toxins: a new focus on an old subject.
    Yavuz A; Tetta C; Ersoy FF; D'intini V; Ratanarat R; De Cal M; Bonello M; Bordoni V; Salvatori G; Andrikos E; Yakupoglu G; Levin NW; Ronco C
    Semin Dial; 2005; 18(3):203-11. PubMed ID: 15934967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparative studies of plasma and urine levels between uremic peak 2a and guanidino compounds].
    Koide K; Toyama J; Inoue N; Koshikawa S; Akizawa T; Takahashi K; Hidaka S; Yamane Y; Nakao M; Ono S
    Nihon Jinzo Gakkai Shi; 1987 Apr; 29(4):485-92. PubMed ID: 3656706
    [No Abstract]   [Full Text] [Related]  

  • 38. [Clinical significance of toll-like receptor 4 expression on the surface of peripheral blood mononuclear cells in uremic patients].
    Wang ZS; Xu DM; Guan GJ; Cui MY; Wei Y; Tang LJ; Jia XY; Li WB
    Zhonghua Yi Xue Za Zhi; 2010 Sep; 90(34):2389-91. PubMed ID: 21092506
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Plasmatic and erythrocytic angiotensinase activity in subjects with chronic uremia before and after treatment with dialysis].
    Ripa R; Degli Atti B; Cavagna R
    Minerva Med; 1970 Mar; 61(26):1307-13. PubMed ID: 4314603
    [No Abstract]   [Full Text] [Related]  

  • 40. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.